ClinicalTrials.gg
CompletedNCT00132119Updated May 19, 2008

Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling

A Phase 2/3 interventional study of nalmefene HCl and Placebo in Pathological Gambling, sponsored by Somaxon Pharmaceuticals. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-05-19.

Sponsored by Somaxon Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.

Read the detailed description

Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling.

02

Conditions studied

  • Pathological Gambling

Browse trials for

03

In context

Gambling

158 studies on the registry are indexed under Gambling; 42 are open to participants now.

This study's enrollment of 233 is above the median of 66 across 128 interventional studies indexed under Gambling.

Browse Gambling studies →

Lead sponsor

Somaxon Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Current diagnosis of pathological gambling as defined by , Fourth Edition, Text Revision (DSM-IV-TR)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    1

    Nalmefene HCl 20 mg

    Drug: nalmefene HCl

  • Experimental
    2

    Nalmefene HCl 40 mg

    Drug: nalmefene HCl

  • Placebo comparator
    3

    Placebo

    Other: Placebo

Interventions

  • Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.

  • OtherPlacebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Assess efficacy in treatment of pathological gambling

Secondary outcomes

  1. Evaluate safety and tolerability in treatment of pathological gambling

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2005
First posted
Aug 19, 2005
Start
Aug 2005
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
May 19, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00132119
Lead sponsor
Somaxon Pharmaceuticals
First posted
Aug 19, 2005
Start date
Aug 2005
Primary completion
Aug 2006
Completion
Aug 2006
Last update
May 19, 2008

Study contacts

Philip Jochelson, MD
study director · Somaxon Pharmaceuticals CMO

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion